Avantor, Inc. (NYSE: AVTR) is a Healthcare company (Medical - Instruments & Supplies) with a market capitalization of $10.8B. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Avantor, Inc. had a Maz Rating of 2.39 out of 5 (C, Hold), ranked against the other companies in its sector. Its strongest factor then was Profitability (4.27), above most of its sector; its weakest was Growth (1.41), among the weakest in its sector. The other factors: Valuation 3.28 (valued in line with its sector); Momentum 2.89 (around the middle of its sector); Financial Health 2.03 (below most of its sector). The current rating is for members: log in to see it.
At $15.91, Avantor, Inc. trades at 31.7x trailing earnings, 1.6x sales and 1.8x book value, with an EV/EBITDA of 15.4. Over the last twelve months it generated about $6.7B of revenue and $341M of net income. It runs a gross margin of 31.6%, an operating margin of 7.6% and a net margin of 5.1%. It shows return on equity of 6.0%, return on invested capital of 4.9% and a free cash flow yield of 4.1%. On the balance sheet: a debt-to-equity ratio of 0.63 and a current ratio of 1.89. Over the past 52 weeks the share price ranged from $7.26 to $17.45, with a beta of 0.95.
Avantor, Inc. does not currently pay a dividend.
26 Wall Street analyst ratings cover the stock: 8 Buy, 16 Hold and 2 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.